![Julie Feder](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Julie Feder
Nessuna posizione attualmente
Profilo
Julie B. Feder is currently Chief Financial Officer at Obsidian Therapeutics, Inc. since 2026.
Former positions include Chief Financial Officer at Aura Biosciences, Inc. from 2018 to 2024, Chief Financial Officer at Verastem, Inc. from 2017 to 2018, Chief Financial Officer at Clinton Health Access Initiative from 2011 to 2017, Vice President-Internal Audit at Genzyme Corp.
from 2008 to 2011, and Senior Manager-Audit, Consulting & Enterprise Risk at Deloitte & Touche LLP from 1991 to 2008.
Education includes undergraduate studies at Sy Syms School of Business.
Posizioni attive di Julie Feder
| Società | Posizione | Inizio |
|---|
Precedenti posizioni note di Julie Feder
| Società | Posizione | Fine |
|---|---|---|
| AURA BIOSCIENCES, INC. | Direttore Finanziario/CFO | 25/10/2024 |
| VERASTEM, INC. | Direttore Finanziario/CFO | 01/06/2018 |
Clinton Health Access Initiative
 Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services Engages in saving lives and reducing diseases through through antiretroviral treatment | Direttore Finanziario/CFO | 01/07/2017 |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, financial advisory and tax consulting services | Corporate Officer/Principal | 01/01/2008 |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Comptroller/Controller/Auditor | - |
Formazione di Julie Feder
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
96
Relazioni di 1° grado
6
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
Genzyme Corp.
Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Aura Biosciences, Inc.
 Aura Biosciences, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company leveraging novel targeted oncology platform to develop new standard of care across multiple cancer indications | Health Technology |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, financial advisory and tax consulting services | Commercial Services |
Verastem, Inc.
 Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs | Health Technology |
Clinton Health Access Initiative
Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services Engages in saving lives and reducing diseases through through antiretroviral treatment | Commercial Services |
Sy Syms School of Business
 Sy Syms School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
